BioNTech's $1.25 billion all-stock acquisition of CureVac strengthens its mRNA manufacturing and cancer immunotherapy pipeline. By integrating CureVac’s manufacturing capabilities and resolving patent disputes, BioNTech is poised to enhance its leadership in mRNA therapeutic innovation and expedite novel cancer treatment development globally.